Author: “The retractions were about bureaucracy, not science”

A researcher has retracted two 2014 papers, after discovering they had not gone through the proper approval process before being submitted.

The papers were part of a collaboration funded by the U.S. National Institutes of Health, which focused on solving protein structures. Adam Godzik, the senior author, told Retraction Watch that all papers had to be approved by a special committee before being submitted to a journal. Given the scale of the collaboration, the committee for the Joint Center for Structural Genomics (JCSG) would assess whether researchers who had made a previous contribution to the work should be added as authors.

Proteins: Structure, Function, and Bioinformatics retracted both papers after Godzik informed the editor in August 2014 that neither article had undergone the required review before being submitted to the journal. Although Wiley agreed to the retractions in an email to Godzik in September 2014,  the papers were only pulled in January—more than three years later. Continue reading Author: “The retractions were about bureaucracy, not science”

Caught Our Notice: “The first author cut the thermoprinter paper printout into pieces and reassembled them”

Title: A mitochondrial ferredoxin is essential for biogenesis of cellular iron-sulfur proteins

What Caught Our Attention: Here’s a cut-and-paste issue that gave us pause. The authors of an 18-year-old paper in PNAS corrected it after realizing some bands in a figure were duplicated (an issue raised on PubPeer one year ago). It turns out, the first author had cut the paper into pieces and reassembled them to present the blots in the “desired order,” and some had become duplicated by mistake. The overall results were unaffected, so the journal swapped the image with a corrected version. Continue reading Caught Our Notice: “The first author cut the thermoprinter paper printout into pieces and reassembled them”

Figures in cancer paper at root of newly failed compound called into question

How much role did a potentially problematic paper play in the demise of a once-promising compound?

Researchers are questioning the validity of a high-profile article, published by Nature in 2006. Although the letter is 12 years old, the concerns have current implications: It was among the early evidence used to develop a cancer compound that recently failed a number of clinical trials.

It’s unclear whether the problems with the paper — if validated — could have contributed to the compound’s demise. But an outside expert has some thoughts — and so do image experts and multiple external reports, including one released this month, which agree the concerns about the figures have merit. (The first author’s ex-husband isn’t too happy with the article, either.)

Continue reading Figures in cancer paper at root of newly failed compound called into question

UCSF-VA investigation finds misconduct in highly cited PNAS paper

PNAS has corrected a highly cited paper after an investigation found evidence of misconduct.

The investigationconducted jointly by the University of California, San Francisco, and the San Francisco Veterans Administration Medical Centeruncovered image manipulation in Figure 2D, which “could only have occurred intentionally.” The institutions, however, could not definitively attribute the research misconduct to any individual.

According to the notice, the UCSF-VA committee determined that a correction to the 2008 PNAS paperwhich explores the genetic underpinnings of prostate cancerwas “appropriate,” and the authors have now replaced the problematic figure with a corrected version. The 2008 paper has been cited 630 times, according to Clarivate Analytics’ Web of Science.

A spokesperson for PNAS told Retraction Watch: Continue reading UCSF-VA investigation finds misconduct in highly cited PNAS paper

“Clear signs of manipulation” in paper co-authored by prominent geneticist

David Latchman

A third paper co-authored by researchers based at a prominent lab whose work has been under investigation on and off for almost three years has been retracted.

According to the notice, the university’s investigation found that a 2008 paper in FEBS Letters contained “clear signs of manipulation” in three figures.

Research from geneticist David Latchman’s group has been dogged by misconduct allegations since late 2013 and subject to two investigations by the University College London (UCL). Continue reading “Clear signs of manipulation” in paper co-authored by prominent geneticist

Caught Our Notice: Voinnet co-author issues another correction

Title: AtsPLA2-α nuclear relocalization by the Arabidopsis transcription factor AtMYB30 leads to repression of the plant defense response

What Caught Our Attention:  A previous collaborator with high-profile plant biologist Olivier Voinnet (who now has eight retractions) has issued an interesting correction to a 2010 PNAS paper. Susana Rivas is last author on the paper, the correction for which notes some images were duplicated, and others were “cropped and/or stretched to match the other blots.” Rivas is currently a group leader at The Laboratory of Plant-Microbe Interactions (LIPM), “a combined INRA-CNRS Research Unit.” Continue reading Caught Our Notice: Voinnet co-author issues another correction

“The ‘1’ key was not pressed hard enough:” Did a typo kill a cancer paper?

Errors in a 2017 paper about a new cancer test may have occurred because of a simple typo while performing calculations of the tool’s effectiveness.

According to the last author, the “1” key was likely not pressed hard enough.

The error, however small, affected key values “so greatly that the conclusions of the paper can no longer be supported,” the editor said, which prompted the journal to retract the paper. Continue reading “The ‘1’ key was not pressed hard enough:” Did a typo kill a cancer paper?

Cancer biologist retracts five papers

Samson Jacob

A cancer researcher based at The Ohio State University has retracted five papers from one journal, citing concerns about figures.

The notices for all five papers state the Journal of Biological Chemistry raised questions about some figures, and the authors were not able to supply raw data in all instances. Four of the notices say the authors offered to submit data from repeat experiments and corrected figures, which the journal declined.

According to Kaoru Sakabe, data integrity manager at JBC, the authors “agreed to withdraw these articles after we declined their offers.”

Continue reading Cancer biologist retracts five papers

Ethics, authorship concerns sink homeopathy paper by researchers arrested last year

For a host of reasons, a journal has retracted a paper co-authored by a researcher who reportedly once faced charges of practicing medicine without proper qualifications.

According to the retraction notice for “Psorinum Therapy in Treating Stomach, Gall Bladder, Pancreatic, and Liver Cancers: A Prospective Clinical Study,” published Dec. 8, 2010 in Evidence-Based Complementary and Alternative Medicine, the paper was plagued by:

Continue reading Ethics, authorship concerns sink homeopathy paper by researchers arrested last year

Data in biofuel paper “had either been grossly misinterpreted or fabricated”

A biology journal has retracted a 2011 paper after the University of California, Los Angeles determined that the data in three figures “cannot be supported.”

In February, the journal Applied and Environmental Microbiology retracted the paper, which explores efforts to engineer bacteria to convert plant biomass into biofuel.

Claudia Modlin, assistant director of UCLA’s Office of Research Policy and Compliance, told Retraction Watch that the university informed the journal about the issues last October, after reviewing the work. Continue reading Data in biofuel paper “had either been grossly misinterpreted or fabricated”